This commentary examines the concept of 'protected time' for clinical investigators in academic medical oncology, questioning whether the prevailing definition—time away from clinic—still fits the realities of modern cancer research and clinical trial operations.
The authors argue the current model fails in both directions: excessive clinical demands erode nominally protected research hours (with >50% of junior investigators conducting research during unpaid personal time, and RVU-based evaluation rising from 47% to 65% at NCCN centers between 2019–2021), while complete insulation from the clinic undermines trial enrollment and research relevance. Oncologist burnout rose from 34% in 2013 to 59% in 2023, with direct patient care hours as the dominant predictor.
This is an opinion/commentary with no primary data collected by the authors; conclusions rely on cited survey data from selected institutional samples that may not be nationally representative. No formal comparison group or longitudinal outcomes are presented.
Institutions, professional societies, and funders should reframe 'protected time' for clinical investigators as insulation from competing administrative and RVU demands—not simply time away from clinic—while preserving meaningful clinical engagement to sustain trial enrollment and research relevance. Addressing research staffing gaps, workflow inefficiencies, and multi-stakeholder funding is as important as negotiating protected-time percentages.
Explore related topics
